MedTrace Logo

Study of Jitongning Tablet to Treat Spondyloarthritis

NCT03932019 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 238

Last updated 2022-11-21

No results posted yet for this study

Summary

This study is to investigate the efficacy and safety of Jitongning Tablet in improving joint function and pain symptoms in active axial spondyloarthritis (SpA) patients and to explore the optimal dosage.

Conditions

  • Spondyloarthritis

Interventions

DRUG

Jitongning tablet(High-dose )

Jitongning tablet,3tablets,bid,treat 12 weeks

DRUG

Jitongning tablet(Low-dose )

Jitongning tablet,2tablets,bid,treat 12 weeks Jitongning tablet placebo,1tablet,bid,treat 12 weeks

DRUG

Placebo

Jitongning tablet placebo,3tablets,bid,treat 12 weeks

Sponsors & Collaborators

  • Tasly Pharmaceutical Group Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Rui Liu · Tasly Group, Co. Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-11
Primary Completion
2021-06-20
Completion
2021-08-20

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03932019 on ClinicalTrials.gov